A citation-based method for searching scientific literature

Martine Paquette, Dany Gauthier, Ann Chamberland, Annik Prat, Emanuella De Lucia Rolfe, Jon J Rasmussen, Lydia Kaduka, Nabil G Seidah, Sophie Bernard, Dirk L Christensen, Alexis Baass. Clin Biochem 2020
Times Cited: 12







List of co-cited articles
68 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Liver fat accumulation is associated with circulating PCSK9.
Massimiliano Ruscica, Nicola Ferri, Chiara Macchi, Marica Meroni, Claudia Lanti, Chiara Ricci, Marco Maggioni, Anna Ludovica Fracanzani, Sara Badiali, Silvia Fargion,[...]. Ann Med 2016
77
58

Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population.
Matthieu Wargny, Pierre-Henri Ducluzeau, Jean-Michel Petit, Cédric Le May, Sarra Smati, Lucie Arnaud, Matthieu Pichelin, Benjamin Bouillet, Adrien Lannes, Odile Blanchet,[...]. Atherosclerosis 2018
17
41

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.
Karin Leander, Anders Mälarstig, Ferdinand M Van't Hooft, Craig Hyde, Mai-Lis Hellénius, Jason S Troutt, Robert J Konrad, John Öhrvik, Anders Hamsten, Ulf de Faire. Circulation 2016
119
33

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Ahmed Zaid, Anna Roubtsova, Rachid Essalmani, Jadwiga Marcinkiewicz, Ann Chamberland, Josée Hamelin, Michel Tremblay, Hélène Jacques, Weijun Jin, Jean Davignon,[...]. Hepatology 2008
277
33

Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina.
Chiara Caselli, Serena Del Turco, Rosetta Ragusa, Valentina Lorenzoni, Michiel De Graaf, Giuseppina Basta, Arthur Scholte, Raffaele De Caterina, Danilo Neglia. Cardiovasc Diabetol 2019
22
33

PCSK9 induces a pro-inflammatory response in macrophages.
Chiara Ricci, Massimiliano Ruscica, Marina Camera, Laura Rossetti, Chiara Macchi, Alessandra Colciago, Ilaria Zanotti, Maria Giovanna Lupo, Maria Pia Adorni, Arrigo F G Cicero,[...]. Sci Rep 2018
98
33

PCSK9 is a critical regulator of the innate immune response and septic shock outcome.
Keith R Walley, Katherine R Thain, James A Russell, Muredach P Reilly, Nuala J Meyer, Jane F Ferguson, Jason D Christie, Taka-aki Nakada, Chris D Fjell, Simone A Thair,[...]. Sci Transl Med 2014
211
33

Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
D R Matthews, J P Hosker, A S Rudenski, B A Naylor, D F Treacher, R C Turner. Diabetologia 1985
25

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Marianne Abifadel, Mathilde Varret, Jean-Pierre Rabès, Delphine Allard, Khadija Ouguerram, Martine Devillers, Corinne Cruaud, Suzanne Benjannet, Louise Wickham, Danièle Erlich,[...]. Nat Genet 2003
25

Decreased PCSK9 expression in human hepatocellular carcinoma.
Mamatha Bhat, Nicolas Skill, Victoria Marcus, Marc Deschenes, Xianming Tan, Jeanne Bouteaud, Sarita Negi, Zuhier Awan, Reid Aikin, Janet Kwan,[...]. BMC Gastroenterol 2015
32
25

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.
Arturo Cesaro, Vanessa Bianconi, Felice Gragnano, Elisabetta Moscarella, Fabio Fimiani, Emanuele Monda, Olga Scudiero, Giuseppe Limongelli, Matteo Pirro, Paolo Calabrò. Biofactors 2020
30
25

PCSK9 and inflammation: a review of experimental and clinical evidence.
Amir Abbas Momtazi-Borojeni, Sarvenaz Sabouri-Rad, Antonio M Gotto, Matteo Pirro, Maciej Banach, Zuhier Awan, George E Barreto, Amirhossein Sahebkar. Eur Heart J Cardiovasc Pharmacother 2019
47
25

Comparison of Serum PCSK9 Levels in Subjects with Normoglycemia, Impaired Fasting Glucose, and Impaired Glucose Tolerance.
Eugene Han, Nan Hee Cho, Seong-Su Moon, Hochan Cho. Endocrinol Metab (Seoul) 2020
3
100

Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.
Gilles Lambert, Nicolas Ancellin, Francesca Charlton, Daniel Comas, Julia Pilot, Anthony Keech, Sanjay Patel, David R Sullivan, Jeffrey S Cohn, Kerry-Anne Rye,[...]. Clin Chem 2008
137
25

Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation.
Gulam Hussain Syed, Huihui Tang, Mohsin Khan, Tarek Hassanein, Jingwen Liu, Aleem Siddiqui. J Virol 2014
64
25

New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway.
Zhi-Han Tang, Juan Peng, Zhong Ren, Jing Yang, Ting-Ting Li, Tao-Hua Li, Zuo Wang, Dang-Heng Wei, Lu-Shan Liu, Xi-Long Zheng,[...]. Atherosclerosis 2017
105
25

PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression.
Patrick Labonté, Syntia Begley, Carl Guévin, Marie-Claude Asselin, Nasha Nassoury, Gaétan Mayer, Annik Prat, Nabil G Seidah. Hepatology 2009
117
25

Inflammation stimulates the expression of PCSK9.
Kenneth R Feingold, Arthur H Moser, Judy K Shigenaga, Sophie M Patzek, Carl Grunfeld. Biochem Biophys Res Commun 2008
152
25

PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease.
Ji Soo Lee, Partha Mukhopadhyay, Csaba Matyas, Eszter Trojnar, Janos Paloczi, Yuan Ru Yang, Brandon A Blank, Cody Savage, Alexander V Sorokin, Nehal N Mehta,[...]. Sci Rep 2019
28
25

The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.
Giorgio Bedogni, Stefano Bellentani, Lucia Miglioli, Flora Masutti, Marilena Passalacqua, Anna Castiglione, Claudio Tiribelli. BMC Gastroenterol 2006
25

Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice.
Paul F Lebeau, Jae Hyun Byun, Khrystyna Platko, Ali A Al-Hashimi, Šárka Lhoták, Melissa E MacDonald, Aurora Mejia-Benitez, Annik Prat, Suleiman A Igdoura, Bernardo Trigatti,[...]. JHEP Rep 2019
26
25

The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury.
Paul F Lebeau, Hanny Wassef, Jae Hyun Byun, Khrystyna Platko, Brandon Ason, Simon Jackson, Joshua Dobroff, Susan Shetterly, William G Richards, Ali A Al-Hashimi,[...]. J Clin Invest 2021
9
33

The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors.
Eleni Theocharidou, Marianna Papademetriou, Andromachi Reklou, Alexandros Sachinidis, Chrisoula Boutari, Olga Giouleme. Curr Pharm Des 2018
24
25

Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease.
Tsuyoshi Nozue, Hiroaki Hattori, Kazuyuki Ogawa, Takeshi Kujiraoka, Tadao Iwasaki, Tsutomu Hirano, Ichiro Michishita. Lipids Health Dis 2016
14
16

Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders.
Daiana Ibarretxe, Josefa Girona, Núria Plana, Anna Cabré, Raimón Ferré, Núria Amigó, Sandra Guaita, Roger Mallol, Mercedes Heras, Luis Masana. Clin Investig Arterioscler 2016
25
16

Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents.
Alexis Baass, Geneviève Dubuc, Michel Tremblay, Edgard E Delvin, Jennifer O'Loughlin, Emile Levy, Jean Davignon, Marie Lambert. Clin Chem 2009
162
16

Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials.
Paul Guedeney, Gennaro Giustino, Sabato Sorrentino, Bimmer E Claessen, Anton Camaj, Deborah N Kalkman, Birgit Vogel, Samantha Sartori, Salvatore De Rosa, Usman Baber,[...]. Eur Heart J 2019
42
16

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
Shirya Rashid, David E Curtis, Rita Garuti, Norma N Anderson, Yuriy Bashmakov, Y K Ho, Robert E Hammer, Young-Ah Moon, Jay D Horton. Proc Natl Acad Sci U S A 2005
517
16

PCSK9 targets important for lipid metabolism.
Rainer Schulz, Klaus-Dieter Schlüter. Clin Res Cardiol Suppl 2017
27
16

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Zobair M Younossi, Aaron B Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer. Hepatology 2016
16

Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
David E Kleiner, Elizabeth M Brunt, Mark Van Natta, Cynthia Behling, Melissa J Contos, Oscar W Cummings, Linda D Ferrell, Yao-Chang Liu, Michael S Torbenson, Aynur Unalp-Arida,[...]. Hepatology 2005
16

Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
Hagai Tavori, Ilaria Giunzioni, Irene M Predazzi, Deanna Plubell, Anna Shivinsky, Joshua Miles, Rachel M Devay, Hong Liang, Shirya Rashid, MacRae F Linton,[...]. Cardiovasc Res 2016
56
16

Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes.
Janne Pott, Valentin Schlegel, Andrej Teren, Katrin Horn, Holger Kirsten, Christina Bluecher, Juergen Kratzsch, Markus Loeffler, Joachim Thiery, Ralph Burkhardt,[...]. Circ Genom Precis Med 2018
21
16

Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice.
Paul F Lebeau, Jae Hyun Byun, Khrystyna Platko, Melissa E MacDonald, Samantha V Poon, Mahi Faiyaz, Nabil G Seidah, Richard C Austin. J Biol Chem 2019
20
16

Adipokines in Liver Cirrhosis.
Christa Buechler, Elisabeth M Haberl, Lisa Rein-Fischboeck, Charalampos Aslanidis. Int J Mol Sci 2017
36
16

Blood sphingolipidomics in healthy humans: impact of sample collection methodology.
Samar M Hammad, Jason S Pierce, Farzan Soodavar, Kent J Smith, Mohammed M Al Gadban, Barbara Rembiesa, Richard L Klein, Yusuf A Hannun, Jacek Bielawski, Alicja Bielawska. J Lipid Res 2010
209
16

Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry.
Philipp Wiesner, Katharina Leidl, Alfred Boettcher, Gerd Schmitz, Gerhard Liebisch. J Lipid Res 2009
235
16

Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis.
Maria R Emma, Lydia Giannitrapani, Daniela Cabibi, Rossana Porcasi, Gianni Pantuso, Giuseppa Augello, Rosaria V Giglio, Noemi Lo Re, Adele R Capitano, Giuseppe Montalto,[...]. Biochim Biophys Acta Mol Cell Biol Lipids 2020
9
22

Low PCSK9 levels are correlated with mortality in patients with end-stage liver disease.
Valentin Schlegel, Theresa Treuner-Kaueroff, Daniel Seehofer, Thomas Berg, Susen Becker, Uta Ceglarek, Joachim Thiery, Thorsten Kaiser. PLoS One 2017
7
28

PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions.
Mika Hilvo, Helena Simolin, Jari Metso, Maija Ruuth, Katariina Öörni, Matti Jauhiainen, Reijo Laaksonen, Amos Baruch. Atherosclerosis 2018
39
16

Plasma PCSK9 preferentially reduces liver LDL receptors in mice.
Aldo Grefhorst, Markey C McNutt, Thomas A Lagace, Jay D Horton. J Lipid Res 2008
145
16

Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency.
Minna T Jänis, Kirill Tarasov, Hung Xuan Ta, Matti Suoniemi, Kim Ekroos, Reini Hurme, Terho Lehtimäki, Hannu Päivä, Marcus E Kleber, Winfried März,[...]. Atherosclerosis 2013
28
16

Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma.
Christa Buechler, Charalampos Aslanidis. Biochim Biophys Acta Mol Cell Biol Lipids 2020
20
16

Adiponectin, a key adipokine in obesity related liver diseases.
Christa Buechler, Josef Wanninger, Markus Neumeier. World J Gastroenterol 2011
166
16

Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice.
Damien Garçon, François Moreau, Audrey Ayer, Wieneke Dijk, Xavier Prieur, Lucie Arnaud, Anna Roubtsova, Nabil Seidah, Annik Prat, Bertrand Cariou,[...]. Arterioscler Thromb Vasc Biol 2020
11
18


Proprotein Convertase Subtilisin/Kexin Type 9: A View beyond the Canonical Cholesterol-Lowering Impact.
Chiara Macchi, Nicola Ferri, Cesare R Sirtori, Alberto Corsini, Maciej Banach, Massimiliano Ruscica. Am J Pathol 2021
24
16

An Update on the Role of PCSK9 in Atherosclerosis.
Ece Yurtseven, Dilek Ural, Kemal Baysal, Lale Tokgözoğlu. J Atheroscler Thromb 2020
8
25

PCSK9 inhibition and inflammation: A narrative review.
Massimiliano Ruscica, Lale Tokgözoğlu, Alberto Corsini, Cesare R Sirtori. Atherosclerosis 2019
44
16

Cardiovascular risk factors in rural Kenyans are associated with differential age gradients, but not modified by sex or ethnicity.
Dirk L Christensen, Daniel Faurholt-Jepsen, Louise Birkegaard, David L Mwaniki, Michael K Boit, Beatrice Kilonzo, Søren Brage, Henrik Friis, Inge Tetens, Knut Borch-Johnsen,[...]. Ann Hum Biol 2016
12
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.